Table 2.
Quality assessment of the studies according to the TESTEX scale (n = 20).
| Criteria | Eligibility Criteria Specified | Randomization Specified | Allocation Concealment | Groups Similar at Baseline | Blinding of all Assessors | Outcome Measures Assessed in 85% of Patients | Adverse Events Reported | Session Attendance Reported | Intent to Treat Analysis | Comparison Between Groups-Primary Outcome | Comparison between Groups-Secondary Outcome(s) | Point and Variability Measures | Activity Monitoring in Control Groups | Relative Exercise Intensity Remained Constant | Exercise Volume Characteristics and Energy Expenditure | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chou 2019 [22] | Yes | Yes | No | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 12/15 |
| Groennebaek 2019 [32] | Yes | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No | Yes | Yes | 11/15 |
| Esposito 2018 [30] | No | No | No | Yes | No | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes | Yes | 8/15 |
| Southern 2015 [35] | Yes | No | No | Yes | No | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes | 7/15 |
| Toth 2012 [37] | No | No | No | Yes | No | Yes | No | No | No | Yes | Yes | Yes | No | Yes | Yes | 7/15 |
| Esposito 2011 [31] | No | No | No | Yes | No | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes | No | 7/15 |
| Williams 2007 [38] | Yes | Yes | No | Yes | No | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes | No | 9/15 |
| Wisløff 2007 [42] | Yes | Yes | No | Yes | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Yes | 11/15 |
| Santoro 2002 [34] | Yes | No | No | No | No | Yes | No | No | No | No | No | Yes | No | Yes | Yes | 5/15 |
| Hambrecht 1997 [45] | No | Yes | No | Yes | Yes | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes | 8/15 |
| Hambrecht 1995 [33] | No | Yes | No | Yes | Yes | No | No | No | No | Yes | Yes | Yes | No | Yes | Yes | 8/15 |
| Stratton 1994 [36] | No | No | No | No | No | Yes | Yes | Yes | No | No | No | Yes | No | No | No | 4/15 |
| Adamopoulos 1993 [29] | No | Yes | No | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | No | Yes | Yes | 10/15 |
| Lin 2021 [20] | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 13/15 |
| Murrow 2019 [40] | Yes | Yes | No | Yes | No | No | No | Yes | No | Yes | Yes | Yes | No | Yes | Yes | 9/15 |
| van Schaardenburgh 2017 [41] | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 13/15 |
| Hiatt 1996 [39] | No | Yes | No | Yes | No | No | Yes | No | No | Yes | Yes | Yes | No | Yes | Yes | 8/15 |
| Hsu 2019 [19] | Yes | Yes | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 11/15 |
| Zoll 2006 [43] | No | Yes | No | Yes | No | No | No | No | Yes | No | No | Yes | No | Yes | Yes | 6/15 |
| Fiorenza 2019 [44] | Yes | No | No | Yes | No | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 10/15 |